Supplementary Figure S3 from FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy

Key Points

Axatilimab likely improves chronic GVHD outcomes in patients previously treated with at least two systemic therapies.
Subgroup analysis reveals efficacy across adult and pediatric patients for chronic GVHD treatments.
The analysis includes a forest plot, highlighting varying responses to axatilimab based on prior therapies.
Findings support the potential of axatilimab as a viable option for chronic GVHD among those unable to achieve relief.

We only have this paper's title and publication details.

Answers are grounded in this paper and cite their sources.

Subgroup analysis shows efficacy outcomes of axatilimab in adult and pediatric patients, indicating its potential for chronic GVHD management.

A subgroup Forest plot for efficacy outcomes

No takes yet. Share an insight, caveat, or question.

Le et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Share